Newton Biocapital’s first fund was instrumental in establishing four spinouts and it has raised $57m towards its $172m goal for its second vehicle.
Newton Biocapital, a Belgium-based life sciences venture capital firm, secured €50m ($57m) in capital for its second fund today from limited partners including Belgian sovereign wealth fund SPFI/FPIM as a cornerstone investor.
Several limited partners from the first vehicle have returned for the second fund, though none were identified.
Like its predecessor fund, NBC II will focus on pre-clinical and clinical-stage companies working on therapies for chronic diseases. The firm’s strategy relies on leveraging research in Europe and Japan, and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
